REMODEL: Renal Mode of Action of Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease.

Study Purpose: The purpose of this study is to determine how Semaglutide works in the kidneys in people with type 2 diabetes and chronic kidney disease.

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if
you meet the following criteria:

Study Duration: Up to 63 weeks

Study Commitment:
1 information visit
1 screening visit
11 outpatient visits
2 phone calls

Age: 18+ years old

Sex: Male & Female

Conditions/Eligibility: Male or female 18 years of age or older
Type 2 diabetic
eGFR 40-75 and UACR 20 - <5000
Currently not using a GLP1-RA

Study Procedures: Screening process, which includes informed consent process, demographics, vitals, physical exam, urinalysis, pregnancy test, blood draw, eye examination, medical history and medication review

11 outpatient visits which consists of randomization to and administration of semaglutide or placebo, MRIs, urine collections, and two kidney biopsies

Compensation: Up to $3,125